Manchester Intermittent versus Daily Diet App Study (MIDDAS): A pilot randomized controlled trial in patients with type 2 diabetes
Authors
McDiarmid, S.Harvie, Michelle N
Johnson, R.
Vyas, A.
Aglan, A.
Moran, J.
Ruane, H.
Hulme, A.
Sellers, K.
Issa, B. G.
Affiliation
The Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, ManchesterIssue Date
2021
Metadata
Show full item recordAbstract
Aims: To test the feasibility and potential efficacy of remotely supported intermittent low energy diets (ILEDs) and continuous low energy diets (CLEDs) in people with type 2 diabetes (T2D) and the feasibility of a Randomized Controlled Trial (RCT) comparing the two approaches. Materials and methods: Seventy-nine adults with overweight/obesity and T2D (≤8 years duration) were randomized 1:1 to CLED (eight weeks/56 days of daily Optifast 820kcal (3430kJ) diet) or isoenergetic ILED (two days of Optifast and five days of a Mediterranean diet/week for 28 weeks). Weight maintenance/continued weight loss was undertaken for the remainder of the 52 weeks. Both groups received frequent telephone and/or the Oviva app support. Feasibility outcomes included study uptake, retention, app usage, dietary adherence, weight loss, and change in HbA1c at 52 weeks. Results: We enrolled 39 ILED and 40 CLED participants and 27 (69%) ILED and 30 CLED (75%) attended 52-week follow-up. Eighty-nine percent (70/79) started using the app and 86% (44/51) still used the app at 52 weeks. Intention-to-treat analysis at 52 weeks showed percentage weight loss was mean (CI) -5.4% (-7.6, -3.1%) for ILED and -6.0% (-7.9, -4.0%) for CLED. HbA1c<48mmol/mol was achieved in 42% of both groups. Mean (CI) changes in the T2D medication effect score (MES) were 0.0008 (-0.3, 0.3) for ILED and -0.5 (-0.8, -0.3) for CLED. Conclusion: The study demonstrates the feasibility and potential efficacy of remotely delivered ILED and CLED programs for weight loss and HbA1c reduction, and the feasibility of an RCT comparing the two approaches.Citation
McDiarmid S, Harvie M, Johnson R, Vyas A, Aglan A, Moran J, et al. Manchester Intermittent versus Daily Diet App Study ( MIDDAS ): A pilot randomized controlled trial in patients with type 2 diabetes [Internet]. Diabetes, Obesity and Metabolism. Wiley; 2021.Journal
Diabetes Obesity and MetabolismDOI
10.1111/dom.14592PubMed ID
34726317Additional Links
https://dx.doi.org/10.1111/dom.14592Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/dom.14592
Scopus Count
Collections
Related articles
- Intermittent Versus Continuous Low-Energy Diet in Patients With Type 2 Diabetes: Protocol for a Pilot Randomized Controlled Trial.
- Authors: McDiarmid S, Harvie M, Johnson R, Vyas A, Aglan A, Moran J, Ruane H, Hulme A, Sellers K, Issa B
- Issue date: 2021 Mar 19
- Manchester Intermittent and Daily diet Type 1 Diabetes App Study (MIDDAS-Type 1): protocol for a randomised feasibility trial of an intermittent and continuous low-energy diet in patients with type 1 diabetes and overweight and obesity.
- Authors: McDiarmid S, Harvie M, Aglan A, Winterbottom H, Mubita W, Hulme A, Davies J, Yates J, Krizak S, Perry D, Issa BG
- Issue date: 2023 Jul 20
- Do people with type 2 diabetes find continuous and intermittent low-energy diets for weight loss and diabetes remission acceptable?
- Authors: Brooks J, Ruane H, McDiarmid S, Vyas A, Issa B, Harvie M
- Issue date: 2024 Aug
- Manchester Intermittent Diet in Gestational Diabetes Acceptability Study (MIDDAS-GDM): a two-arm randomised feasibility protocol trial of an intermittent low-energy diet (ILED) in women with gestational diabetes and obesity in Greater Manchester.
- Authors: Dapre E, Issa BG, Harvie M, Su TL, McMillan B, Pilkington A, Hanna F, Vyas A, Mackie S, Yates J, Evans B, Mubita W, Lombardelli C
- Issue date: 2024 Feb 10
- A randomized controlled trial of an app-based intervention on physical activity and glycemic control in people with type 2 diabetes.
- Authors: Kim G, Kim S, Lee YB, Jin SM, Hur KY, Kim JH
- Issue date: 2024 May 1